Pacibekitug is an investigational monoclonal antibody developed by Tourmaline Bio, Inc., through a license from Pfizer, targeting interleukin-6 (IL-6) for the treatment of inflammatory conditions. It is administered subcutaneously and is designed to reduce systemic inflammation by inhibiting IL-6, a pro-inflammatory cytokine implicated in various diseases, including cardiovascular disease and chronic kidney disease (CKD).
Pacibekitug is an investigational monoclonal antibody developed by Tourmaline Bio, Inc., through a license from Pfizer, targeting interleukin-6 (IL-6) for the treatment of inflammatory conditions. It is administered subcutaneously and is designed to reduce systemic inflammation by inhibiting IL-6, a pro-inflammatory cytokine implicated in various diseases, including cardiovascular disease and chronic kidney disease (CKD).
Source: Wikipedia "Pacibekitug" · CC BY-SA 4.0
Share this article: X · Bluesky